HCW Biologics reported revenue of $0.14M and net income of -$5.22M for the quarter ended Jun 2026. This income statement covers 24 quarters of results from Jun 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | ||||||||||||||||||||||||
| Revenue | 3.12M | 0.45M | 1.81M | 1.34M | 0.04M | 0.62M | 0.85M | 1.32M | 1.13M | 0.62M | 0.43M | 0.39M | 0.01M | 0.01M | 0.02M | 0.03M | 0.14M | |||||||
| Cost of RevenueCost of Rev | 1.33M | 0.29M | 1.45M | 1.07M | 0.03M | 0.50M | 0.68M | 1.07M | 0.51M | 0.44M | 0.34M | 0.32M | 0.00M | 0.01M | 0.01M | 0.02M | 0.23M | |||||||
| Gross Profit | 1.79M | 0.17M | 0.36M | 0.27M | 0.01M | 0.12M | 0.17M | 0.25M | 0.61M | 0.18M | 0.09M | 0.08M | 0.00M | 0.00M | 0.00M | 0.01M | -0.09M | |||||||
| Operating items | ||||||||||||||||||||||||
| Research & DevelopmentR&D | 1.67M | 2.69M | 1.48M | 1.79M | 1.97M | 2.65M | 2.93M | 2.26M | 1.62M | 1.67M | 2.14M | 2.12M | 2.03M | 1.19M | 1.05M | 1.48M | 1.23M | 1.40M | 1.33M | 1.20M | ||||
| Selling, General & AdministrativeSG&A | 1.08M | 1.40M | 1.63M | 1.88M | 1.71M | 1.73M | 3.01M | 3.12M | 1.59M | 1.51M | 1.67M | 1.57M | 1.59M | 1.63M | 2.03M | 2.23M | 2.10M | 1.88M | 1.51M | 1.87M | ||||
| Other Operating ExpensesOther Opex | -0.18M | 516.00 | 0.14M | 0.34M | 0.38M | 0.30M | 0.23M | 0.09M | 0.03M | 0.02M | 0.01M | 0.03M | 0.02M | 0.02M | 0.01M | 0.01M | 0.01M | |||||||
| Operating ExpensesOpex | 2.75M | 4.09M | 3.11M | 3.67M | 3.68M | 4.38M | 5.94M | 5.37M | 4.63M | 5.25M | 11.02M | 8.11M | 15.32M | 3.77M | 3.23M | 1.97M | 3.47M | 3.30M | 4.47M | 3.07M | ||||
| Operating IncomeOp. Inc | -2.75M | -4.09M | -3.11M | -1.88M | -3.51M | -4.02M | -5.67M | -5.36M | -4.51M | -5.08M | -10.77M | -7.49M | -15.14M | -3.68M | -3.15M | -1.97M | -3.46M | -3.29M | -4.46M | -3.17M | ||||
| EBIT | -2.75M | -4.09M | -3.11M | -1.88M | -3.51M | -4.02M | -5.67M | -5.36M | -4.51M | -5.08M | -10.77M | -7.49M | -15.14M | -3.68M | -3.15M | -1.97M | -3.46M | -3.29M | -4.46M | -3.17M | ||||
| Non-operating items | ||||||||||||||||||||||||
| Non Operating Interest Expenses | 0.03M | 0.09M | 0.09M | 0.10M | 0.10M | -0.00M | 0.16M | 0.23M | 0.26M | 0.26M | 0.23M | 0.13M | 0.21M | 0.10M | ||||||||||
| Non Operating Investment IncomeNon-Op. Investment Inc. | 1.75M | |||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 631.00 | |||||||||||||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | -2.44M | |||||||||||||||||||||||
| Non Operating IncomeNon Op. Inc. | -1.30M | |||||||||||||||||||||||
| Net income details | ||||||||||||||||||||||||
| EBT | -2.75M | -4.09M | -3.11M | -1.88M | -3.51M | -4.05M | -5.76M | -5.45M | -4.61M | -5.17M | -10.77M | -7.49M | -15.30M | -3.91M | -3.41M | -2.22M | -1.93M | -3.42M | -4.67M | -5.22M | ||||
| Profit After TaxPAT | -2.75M | -4.09M | -3.17M | -2.06M | -3.51M | -3.91M | -5.42M | -5.07M | -4.30M | -4.94M | -10.68M | -7.47M | -15.28M | -3.90M | -3.37M | -2.20M | -1.93M | -4.55M | 0.72M | -5.22M | ||||
| Income from Continuing OperationsIncome (Continuing) | -2.75M | -4.09M | -3.11M | -1.88M | -3.51M | -4.05M | -5.76M | -5.45M | -4.61M | -5.17M | -10.77M | -7.49M | -15.30M | -3.91M | -3.41M | -2.22M | -1.93M | -3.42M | -4.67M | -5.22M | ||||
| Consolidated Net IncomeConsol Net Inc. | -2.75M | -4.09M | -3.11M | -1.88M | -3.51M | -4.05M | -5.76M | -5.45M | -4.61M | -5.17M | -10.77M | -7.49M | -15.30M | -3.91M | -3.41M | -2.22M | -1.93M | -3.42M | -4.67M | -5.22M | ||||
| Income towards Parent CompanyParent Net Inc | -2.75M | -4.09M | -3.11M | -1.88M | -3.51M | -4.05M | -5.76M | -5.45M | -4.61M | -5.17M | -10.77M | -7.49M | -15.30M | -3.91M | -3.41M | -2.22M | -1.93M | -3.42M | -4.67M | -5.22M | ||||
| Preferred Dividend PaymentsPref Dividends | 0.48M | |||||||||||||||||||||||
| Net Income towards Common StockholdersNet Income | -3.23M | -4.09M | -3.17M | -2.06M | -3.51M | -4.05M | -5.76M | -5.45M | -4.61M | -5.17M | -10.77M | -7.49M | -15.28M | -3.90M | -3.37M | -2.22M | -12.08M | -4.55M | -3.47M | -15.37M | ||||
| Additional items | ||||||||||||||||||||||||
| EPS (Basic) | -157.67 | -33.23 | -40.57 | -13.80 | -23.52 | -27.14 | -38.60 | -36.48 | -30.78 | -34.56 | -71.92 | -48.32 | -96.96 | -24.76 | -20.87 | -0.30 | -40.72 | -12.09 | -9.91 | -11.58 | ||||
| EPS (Diluted) | -157.67 | -33.23 | -40.57 | -13.80 | -23.52 | -27.14 | -38.60 | -36.48 | -30.78 | -34.56 | -71.92 | -48.32 | -96.96 | -24.76 | -20.87 | -0.30 | -40.72 | -12.09 | -9.91 | -11.58 | ||||
| Shares Outstanding | 0.02M | 0.12M | 0.08M | 0.15M | 0.15M | 0.15M | 0.15M | 0.15M | 0.15M | 0.15M | 0.15M | 0.16M | 0.16M | 0.16M | 0.16M | 7.45M | 0.30M | 0.38M | 0.35M | 1.33M | ||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 0.02M | 0.12M | 0.08M | 0.15M | 0.15M | 0.15M | 0.15M | 0.15M | 0.15M | 0.15M | 0.15M | 0.16M | 0.16M | 0.16M | 0.16M | 7.45M | 0.30M | 0.38M | 0.35M | 1.33M | ||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 0.02M | 0.12M | 0.08M | 0.15M | 0.15M | 0.15M | 0.15M | 0.15M | 0.15M | 0.15M | 0.16M | 0.16M | 0.16M | 0.16M | 0.19M | 7.49M | 0.30M | 0.45M | 0.35M | 1.33M | ||||
| EBITDA | -2.75M | -4.09M | -3.11M | -1.88M | -3.51M | -4.02M | -5.67M | -5.36M | -4.51M | -5.08M | -10.77M | -7.49M | -15.14M | -3.68M | -3.15M | -1.97M | -3.46M | -3.29M | -4.46M | -3.17M | ||||
| Interest ExpensesInt Expense | 0.03M | 0.09M | 0.09M | 0.10M | 0.10M | -0.00M | 0.16M | 0.23M | 0.26M | 0.26M | 0.23M | 0.13M | 0.21M | 0.10M |